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ABSTRACT 
Background & Aims 
Yttrium-90 trans-arterial radioembolization (TARE) has shown promising efficacy in the treatment 
of patients with hepatocellular carcinoma (HCC) associated with tumoral portal vein thrombosis 
(PVTT). Aim of this study is to identify prognostic factors for survival in patients with HCC and 
PVTT undergoing TARE, and build a prognostic classification for these patients. 
Methods 
This is a single Center retrospective study conducted over 6 years (2010-2015), on consecutive 
patients undergoing TARE. Patients were included if they met the following criteria: presence of at 
least one measurable HCC, presence of PVTT not occluding the main portal trunk, absence of 
extra-hepatic metastases, Child-Pugh score within B7, ECOG performance status 0-1. Uni- and 
multivariable analysis was used to explore the variables that showed an independent relationship 
with survival. A prognostic score was then derived, and three prognostic categories were identified.  
Results 
A total of 120 patients were included in the study. Median OS was 14.1 months (95%CI: 10.7-17.5) 
and median PFS was 6.5 months (95%CI: 3.8-9.2). The only variables independently correlated 
with OS were bilirubin, extension of PVTT and tumor burden. Three prognostic categories were 
identified: favourable prognosis (0 points), intermediate prognosis (2-3 points) and dismal 
prognosis (> 3 points). Median OS in the three categories was 32.2 months, 14.9 months and 7.8 
months respectively (p<.0001). Also PFS (p=.045) and risk of liver decompensation (p<.0001) 
significantly differed along the same prognostic categories. 
Conclusions 
Radioembolization with Yttrium-90 is an effective therapy for patients with HCC and PVTT. The 
proposed prognostic stratification may help to better identify good candidates for the treatment, 
and those for whom TARE may be futile. 
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LAY SUMMARY 
Yttrium-90 trans-arterial radioembolization (TARE) is a microembolic procedure that minimizes 
alterations of the hepatic arterial flow, and thus can be safely performed also in patients with 
hepatocellular carcinoma (HCC) and tumoral portal vein invasion (PVTT). In this study, we 
retrospectively evaluated the independent predictors of long-term outcomes in patients with HCC 
and PVTT treated with TARE. Bilirubin level, extension of PVTT and tumor burden were 
independently related to post-treatment survival: the combination of these factors allowed us to 
build a prognostic stratification that may help to better identify good candidates for the treatment, 
and those for whom TARE may be futile. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is a global health problem and one of the leading causes of 
cancer-related death especially in cirrhotic patients(1, 2). By reason of the improvements in 
surveillance protocols, diagnostic tools and therapeutic armamentaria, diagnosis of early HCC is 
feasible in 30–60% of cases(3). However, a substantial proportion of patients still present tumoral 
portal vein thrombosis (PVTT) either at onset of the disease or as result of HCC recurrence or 
progression, leading to an advanced stage of the disease not amenable to curative treatments(4). 
Patients with HCC and PVTT may present asymptomatic although in most instances have a 
significant degree of synthetic dysfunction and an impending liver decompensation that precludes 
any attempt of surgical cure. Moreover, when the portal circulation is compromised by thrombosis, 
trans-arterial embolo-therapies may increase the risk of liver failure; therefore, the presence of 
PVTT is generally considered as a contraindication to trans-arterial chemoembolization (TACE).(5, 
6) 
Two pivotal phase III trials have demonstrated a survival advantage for patients with advanced 
HCC treated with the oral multi-tyrosine kinase inhibitor sorafenib(7, 8) with respect to placebo, 
and a subgroup analysis has confirmed this result also in patients with PVTT(9, 10). Sorafenib has 
been therefore recognized as the standard of care for the treatment of advanced HCC by the 
American Association for the Study of Liver Diseases (AASLD)(11), the European Association for 
the Study of the Liver (EASL)(5) and the Asian Pacific Association for the Study of the Liver 
(APASL)(12). Nevertheless, sustained responses to sorafenib are rare, median survival in patients 
with advanced HCC remains limited to 6.5 - 10.7 months, and the treatment itself is associated 
with side effects that frequently lead to early treatment interruption(7, 8, 13, 14). 
Trans-arterial radioembolization (TARE) is a form of brachyterapy performed by selective intra-
arterial injection of microspheres loaded with Yttrium-90 (Y90): a pure beta-emitter characterized by 
limited penetration, that enables selective tumor treatment with limited damage of the surrounding 
tissue(15). Unlike other trans-arterial therapies, TARE is a microembolic procedure that minimizes 
alterations of the hepatic arterial flow(16): several large series on TARE for patients with HCC and 
PVTT, mostly restrospective, showed an acceptable safety profile and good results in terms of 
local control of the disease(17-21). Only recently, two phase III randomized clinical trials (RCT) 
comparing TARE to the standard of care sorafenib in the population of patients with locally 
advanced HCC, have been made accessible(22),(23). In both trials the primary endpoint was not 
met, since TARE did not provide a significant gain in survival compared to sorafenib in the overall 
population nor in the subgroup of patients with PVTT. Incidentally, both studies clearly showed a 
significantly better treatment tolerance and quality of life in patients undergoing TARE. 
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Aim of this study is to identify, in a prospectively collected series of patients with PVTT treated with 
TARE, the prognostic factors with relevant impact on patients’ survival (overall survival, OS), in 
order to build a prognostic classification that may allow to identify patients who would benefit most 
from the treatment. 
METHODS 
This is a retrospective single Center study on prospectively collected consecutive patients with 
HCC and PVTT, treated with yttrium-90 radioembolization (TARE) by means of glass microspheres 
(Therasphere® BTG International Ltd.) in a six years interval, from January 1st 2010 to December 
31th 2015. Inclusion criteria were the following: a) presence of at least one measurable HCC lesion 
according to RECIST 1.1 criteria(24); b) presence of PVTT not occluding the main portal trunk c) 
absence of extra-hepatic metastases; d) Child-Pugh score within B7 e) ECOG performance status 
0-1; f) age > 18 yrs. Patients with PVTT not meeting such criteria were not considered for TARE, 
and were indicated sorafenib or best supportive care according to liver function.  
Approval for the study was obtained from the local Institutional Review Board.  
Pre-treatment staging 
Pre-treatment patients’ assessment and tumor staging were performed the day before 99Tc-
macroaggregated albumin (99Tc-MAA) scintigraphy and included: chest CT-scan, abdominal 
contrast-enhanced CT-scan or MRI, liver volumetry and calculation of tumor burden (% of tumor 
volume with respect to liver volume, measured with the CT-Volume Software Siemens Syngo 
Multimodality Workplace), collection of baseline demographic characteristics and history of 
previous treatments for HCC, etiology of the underlying liver disease, assessment of patients’ 
performance status according to the Eastern Cooperative Oncology Group (ECOG) score, blood 
tests including alpha-fetoprotein (AFP).  Liver function was evaluated according to the Child-Pugh 
score (CTP), the MELD score(25) and the ALBI grade(26).  
Diagnosis of HCC was made according to radiographic findings or biopsy as defined by 
EASL/AASLD guidelines(5). Tumor-related PVTT was defined at baseline contrast-enhanced CT-
scan or MRI as the presence of a filling defect in the portal venous phase, with evidence of 
enhancement during the arterial phase of dynamic imaging, associated to an HCC. PVTT 
extension was graded as PV1 (segmentary), PV2 (secondary order branch), PV3 (first order 
branch) as previously described(21). Invasion of hepatic veins was defined as presence of tumoral 
invasion of one or more of the main hepatic veins. 
Treatment and dosimetry  
Informed consent was obtained from all subjects before every angiographic procedure. TARE was 
performed in two sessions, as previously described(21): a simulation of treatment was performed 
by the injection of 99Tc-MAA into the hepatic arterial vasculature reproducing Y90 microspheres 
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distribution, in order to estimate the degree of extrahepatic deposition and tumor uptake by means 
of planar and SPECT scintigrams; coiling of extrahepatic arteries was performed when required to 
avoid unintentional deposition. The dose calculation was based on an individualized treatment 
planning based on 99mTc-MAA SPECT voxel dosimetry. The treatment planning evolved along the 
5 years of the study and was aimed at delivering the maximal tolerable parenchyma absorbed 
dose to limit the risk of liver decompensation. This value was initially kept low (dosimetric method 
1), resulting in about 40 Gy to parenchyma. Then it was raised to about 70 Gy (dosimetric methods 
2 and 3) after our determination of  the dose-toxicity curve for HCC patients treated with 90Y glass 
microspheres (27). In both methods 1 and 2, patients were treated with one million microspheres 
per GBq while with method 3, patients were treated with 2.8 million of microspheres per GBq.  
The treatment was performed 2-3 weeks after the simulation, by the injection of glass 
microspheres loaded with 90Yttrium (TheraSphere ®) on the day of admission. Before injection, 
patients are given cefazoline 2 grams intravenously. After TARE, patients are hospitalized for 48 
hours for clinical observation and according to safety regulation in our Region. During this period 
patients undergo blood tests 24 and 48 hours after TARE to check early toxicity, and given anti-
emetics and analgesics if needed. 
Follow-up 
After TARE, patients were followed-up on an outpatient basis at months 1, 3, 6 and then every four 
months by means of contrast-enhanced thoraco-abdominal CT scan, physical examination and 
laboratory analysis including AFP. Adjunctive visits or hospitalizations were added whenever 
required depending on patients’ or physicians’ request and on detectable changes in clinical 
conditions.  
Liver decompensation (LD) was defined as the occurrence of any of the following: clinically 
detectable ascites, bleeding from esophageal varices, hepatic encephalopathy, total bilirubin >3 
mg/dL, and prothrombin time international normalized ratio >2.2(21). Tumor progression was 
assessed according to RECIST criteria 1.1. The variations of PVTT extension during follow-up 
were not considered in tumor response evaluation. All CT scans were independently revised by 
two experienced radiologists (CSpr, MV); whenever evaluation was not overt, agreement was 
reached with a third radiologist on staff.  
At progression, patients were treated according to disease presentation after multidisciplinary 
discussion. In particular, patients with a maintained liver function and an intrahepatic progression 
amenable to locoregional treatments were offered repeated TARE or percutaneous ablation; 
patients with a maintained liver function not amenable to locoregional treatments were offered 
sorafenib; patient presenting with liver decompensation were offered best supportive care. 
Statistical analysis  
Categorical variables were reported as the number of cases and percentages; continuous 
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variables were expressed as median and interquartile range (IQR). Overall survival, progression-
free survival (PFS) and time to liver decompensation were estimated by the Kaplan-Meier method, 
and calculated from the date of TARE. Survival curves were compared by the log-rank test. Median 
follow-up was calculated with the reverse Kaplan Meier method.  
For the survival analysis, continuous variables were transformed into qualitative or ordinal 
variables according to ranges of normality for laboratory values, clinical relevance or the median 
value of the given parameter. The event of interest was death for any cause: univariate analysis 
was performed for all the variables under study, and then multivariable analysis using the Cox 
proportional-hazards model was used to explore the variables that showed an independent 
relationship with survival. The proportionality assumption was verified by Schoenfeld residual 
analysis. A prognostic score was then derived using the independent variables weighed according 
to the estimated β regression coefficient of the final Cox model. The risk estimate associated with 
each point was then calculated using the Cox proportional hazards model. Three prognostic 
categories were identified according to the changes in the risk estimates for each point increase of 
the score. The OS curves, PFS curves and risk of liver decompensation were then obtained with 
the Kaplan-Meier method and compared by means of log-rank test.   
All analyses were 2-tailed and the threshold of significance was assessed at p<0.05. The statistical 
analysis was performed using IBM® SPSS® Statistics, version 20. 
RESULTS 
A total of 148 patients meeting the inclusion criteria underwent 99Tc-MAA angioscintigraphy during 
the study period. Of these patients, 28 (18.9%) did not undergo subsequent TARE for the following 
reasons: 15 patients (53.6%) because of low/absent accumulation of 99Tc-MAA in the tumor 
nodules,  8 patients (28.6%) because of extrahepatic (gastrointestinal) accumulation of 99Tc-MAA 
and 5 patients (17.8%) because of lung shunting. Finally, 120 patients were eligible for the study 
and received the TARE treatment. Baseline characteristics are depicted in Table 1: overall, the 
median age was 64 years (IQR: 56-72), patients were mainly males (85.0%) and were 
predominantly classified as “fully active” (ECOG PS 0, 95.8%). In the majority of cases (45.8%), 
HCV was the etiology of liver disease; liver function was within CTP A in 93.3% of cases, median 
MELD score was 8 (IQR: 7-10) and ALBI grade was 1 and 2 in 51.7% and 47.5% of cases 
respectively. Thirty-seven patients (30.8%) had undergone one or more sessions of trans-arterial 
chemoembolization (TACE) before TARE. All patients were in the advanced stage according to the 
BCLC classification (BCLC-C): PVTT was extended to segmentary branches in 53 patients (PV1, 
44.2%), to secondary order branches in 37 patients (PV2, 30.8%) and to first order branches in 30 
patients (PV3, 25%). In most cases HCC was infiltrative (84 patients, 70.0%) and multifocal (99 
patients, 82.5%), with a median diameter of the largest lesion of 7.3 cm (IQR: 5.8-10.9). The 
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median administered activity of Y90 was 2.6 GBq (1.9-3.7) and the treatment planning method was 
1, 2 and 3 in 18 (15%), 77 (64.2%) and 25 (20.8%) cases respectively. 
Survival analysis  
Thirty-days mortality after treatment was 0%. Median follow-up was 27.0 months (95%CI: 9.98-
44.02): during this time, 90 patients died, 77 patients showed tumor progression and 37 patients  
experienced at least one episode of liver decompensation. Median OS was 14.1 months (95%CI: 
10.7-17.5), and 1yr and 3yrs-OS were 53.2% and 18.5% respectively (Figure 1, panel A). Median 
PFS was 6.5 months (95%CI: 3.8-9.2), and 1yr and 3yrs progression-free survival (PFS) were 
35.2% and 0% respectively (Figure 1, panel B). The rate of liver decompensation (LD) was 10.8% 
at 3 months and 31.6% at 6 months.  
No patients in the present series underwent subsequent resection. Only one patient (with PVT type 
1) underwent liver transplant (LT) after showing a sustained complete response 1 year after TARE. 
He is alive and well after  24 months but his follow-up for this study was censored at the time of LT. 
The first site of tumor progression was intra-hepatic in 59 patients (76.6% of progressions): 
detectable in 11 patients in the TARE-treated lobe while in 43 patients upon appearance of new 
nodules in the contralateral lobe. In 18 patients (23.4% of progressions) the first site of progression 
was extra-hepatic only (10 patients) or combined intra-hepatic and extra-hepatic (8 patients). 
Treatment at progression consisted in retreatment with TARE in 14 patients, sorafenib or second-
line experimental systemic therapies in 25 patients, percutaneous ablation in 3 patients and best 
available care in the remaining 35 patients. Such distribution was dependent on liver function 
status, as only 34 patients (44.1%) maintained a well-compensated Child A status at the time of 
post-TARE tumor progression(28).  
Development of the prognostic classification  
The results of the univariate analysis on baseline patients characteristics are presented in Table 2.  
Those variables identified as significant at univariate analysis were fitted in a multivariable Cox 
proportional hazards regression model: the only variables independently correlated with survival 
were bilirubin, PVTT grade and tumor burden at the time of TARE; the proportionality of hazard 
ratios for all levels of all prognostic factors was verified. The beta coefficients were transformed 
into relative points as shown in Figure 2. The hazard function identified a clear-cut change in the 
hazard ratio at the sum of 2 points and > 3 points. Thus, three prognostic categories were 
identified: favourable prognosis (0 points), intermediate prognosis (2-3 points) and dismal 
prognosis (> 3 points). Median OS in the three categories was 32.2 months, 14.9 months and 7.8 
months respectively (p<.0001, Figure 2). Also PFS (p=.045) and risk of liver decompensation 
(p<.0001) were significantly stratified according to the three proposed prognostic categories, as 
reported in Table 3. Median PFS was 14.1 months (with a 42.1% 3-years OS) in patients with 
normal bilirubin, limited tumor burden and PVT limited to segmental branches (favourable 
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prognostic group); conversely TARE in patients with more than one risk factor (> 3 points) yielded 
a median PFS of 4.1 months, a risk of liver decompensation of 21.6% at 3 months and no survivors 
at 3 years. In Figure 3, three cases of patients with HCC and different grades of PVTT (type 1, 2 
and 3 respectively) are showed before and after TARE treatment. 
DISCUSSION 
Despite consistent advancements in the clinical management of HCC, the therapeutic options for 
patients with locally advanced disease because of PVTT are very limited.   
Radioembolization with Y90 has been recognized as a safe and effective treatment for unresectable 
HCC, as acknowledged in several guidelines(5, 11, 29). In several non-comparative studies(17-21, 
30) published in the last decade on patients with HCC and PVTT, treatment with TARE has 
demonstrated an excellent safety profile, with median OS ranging from 10 to 13 months. These 
survival outcomes appeared superior to those obtained with sorafenib(7, 8) and this has fuelled 
retrospective comparative studies(31, 32) and two randomized clinical trials comparing TARE and 
sorafenib in the setting of locally advanced HCC. All these studies – although not specifically 
focused on the subset of patients with PVTT – failed to confirm a meaningful survival benefit 
provided by TARE with Y90 microsphere (22, 23).   
In this study we report the long term outcomes of a consecutive series of patients with HCC and 
PVTT treated with TARE. As shown in Figure 1, median and 3-years OS were 14.1 months and 
18.5% respectively. Overall, these results are superior than those previously reported by our 
group(21), and amongst the best reported in literature for patients offered such treatment outside 
clinical trials: this is probably related to the stringent application of refined selection criteria, derived 
from our previous experience. In fact, in the present series, patient with PVTT were treated with 
TARE only in presence of compensated liver function (within Child-Pugh A-B7 stage) and with no 
occlusion of the main portal trunk. This resulted also in a 0% treatment-related mortality, and in an 
acceptable rate of liver decompensation at 3 months of 10.8%.  
Considering the resource impact of TARE in the current practice of HCC treatment, the main 
endpoint of our study was to identify the independent prognostic factors for OS in patients with 
HCC and PVTT treated with TARE and to assess whether or not different prognostic categories 
could correlate with predictable patient outcomes in advanced HCC maintaining sufficient liver 
function. At multivariable analysis, only 3 variables (PVTT extension, tumor burden in terms of liver 
volume replacement and baseline serum total bilirubin) were found to have an independent impact 
on post-treatment survival.   
The extension of PVTT is known to directly affect patients prognosis: with respect to segmental 
invasion, thrombosis of more proximal branches increases the risk of tumor spread, and induces 
elevation of portal venous pressure causing higher risk of variceal hemorrhage, ascites, and liver 
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failure(33).  The influence of PVTT extension on post-treatment outcomes has been demonstrated 
in several series of HCC patients treated with TARE(21, 33, 34), but also in patients treated by 
means of radical surgical resection(35). To be noted, patients with main PVTT were not treated at 
our Center. Based on the available literature(15, 17, 21) TARE in this setting provides a median 
OS from 3 to 6 months, not seeming to provide a meaningful survival benefit. This is probably due 
to the fact that main PVTT is vascularized by arterial feedings coming from the common hepatic 
artery, and thus and thus out of reach for microspheres injected when performing lobar or selective 
treatments (through first or second order arterial branches).  
Tumoral burden replacing > 50% of total liver volume also independently affected survival. Not 
surprisingly, other morphological tumor variables (i.e. tumor size, number of nodules, presentation 
pattern) lost significance with respect to the overall tumor bulk, a common feature in the advanced 
stages of the disease. Most likely this correlated with a reduced functional liver remnant and a 
consequent higher risk of early liver decompensation; moreover, excessive tumor load may impede 
an effective treatment by means of a single session of TARE, and liver dysfunction may precede 
re-treatments.  
Bilirubin was the only liver-related factor that showed an independent correlation with post-
treatment survival. Again, this was relatively expected because the study population was relatively 
homogeneous in terms of liver function, being 97.2% of patients in Child-Pugh A and having an 
ALBI grade <3 in 99.2% of cases. Baseline bilirubin levels showed an independent influence on 
survival in other series of patients treated with TARE(19, 20): higher bilirubin at baseline is a sign 
of liver dysfunction and a predisposing factor for post-treatment bilirubin toxicity, which is a 
common adverse event after TARE, particularly in patients with PVTT(17).  
A distinctive feature of this study is the development of a prognostic score derived from the 
estimated β regression coefficients of the final Cox model for extension of PVTT, tumor burden and 
serum bilirubin values at the time of treatment. According to the changes in risk estimates three 
prognostic categories were thus identified, that allowed a significant prognostic stratification in 
terms of OS, PFS and risk of liver decompensation at 3 months as shown in Figure 2 and Table 3. 
In particular, patients with 0 points (absence of adverse prognostic factors) were those with a 
favourable prognosis. These patients showed a median OS of 32.2 months and a median PFS of 
14.1 months, with a negligible risk of TARE-related liver decompensation (3.2 % after 3 months). 
The favourable prognosis subgroup achieved in fact a remarkable survival outcome that is 
comparable to unresectable HCC undergoing trans-arterial chemoembolization in the absence of 
PVTT(36, 37). This result indirectly suggests that HCC patients with segmental PVTT and good 
liver function may be considered a sub-category of the intermediate stage HCC according to the 
BCLC classification(38). Thus, besides confirming that TARE may be considered as the first line 
treatment in such a patients’ subgroup, the observed median PFS of 14.1 months may well justify 
consideration of TARE as a down-staging treatment to liver transplantation in selected patients 
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with segmental PVTT.  
Patients expressing one of the aforementioned prognostic factors (2-3 points) can be considered a 
subgroup at intermediate prognosis. In this category of patients TARE works with a palliative 
purpose, even though the observed median OS of 14.9 months remains definitively higher than 
what expected with a first line systemic therapy. Considering the good tolerability of the treatment, 
and the acceptable risk of liver decompensation at 3 months (less than 10%), in field practice 
TARE can be proposed as a reasonable alternative to systemic treatments when the composite 
assessment of post-TARE prognosis turns out to be in the intermediate-risk category (Figure 2). 
According to the results of our prospective series, patients expressing more than one of the 
prognostic factors should be considered at a dismal prognosis. In this category median OS was 7.8 
months, therefore with a much inferior benefit than what expected with systemic therapy. 
Considering also a risk of liver decompensation of 21.6% at 3 months, TARE for this patients’ 
subgroup may be futile and potentially harmful, and thus should be avoided.  
Our study has some limitations. Tumor or PVT absorbed doses were not specifically evaluated. 
Garin et al., in a study focusing on the impact of tumour dose based on 99mTc MAA quantification, 
found that a predicted tumor dose > 205 Gy and a good PVT targeting may significantly improve 
OS (39). In future studies, personalized dosimetry may be integrated into the proposed scoring 
system to further improve the prognostic prediction. Although this is one of the largest cohorts of 
consecutive patients with PVTT treated with TARE, the retrospective nature of the study and the 
relatively small sample size obviously limits the strength of evidence. In particular, the limited 
number of patients does not allow for a sensitivity analysis in order to evaluate the weight of the 
different components of the score within each prognostic category. Secondly, the previously 
discussed implications of our prognostic stratification for what regards treatment allocation are 
limited by the absence of a comparator. Most likely, the true survival benefit provided (or not) by 
TARE in the different prognostic classes of patients with PVTT compared to systemic treatments 
should be investigated in specifically designed prospective comparative studies: a condition that 
recent RCTs on TARE combined or compared to sorafenib did not specifically address. Finally, in 
this report the evaluation of radiological response to TARE was not specifically collected, being 
that beyond the objectives of a study specifically focused on clinical outcomes and on pre-
treatment prognostication of survival.  
Even considering these limitations, this study suggests that TARE is a safe and effective treatment 
for patients with HCC and PVTT. In patients with good liver function and no invasion of the main 
portal trunk, PVTT extension, tumor bulk and bilirubin level have an independent influence on long-
term outcomes. The proposed score – easily determined on pre-treatment clinical variables – can 
help in the identification and selection of good candidates for the treatment, and conversely of 
those patients for whom TARE may be a futile therapy to offer. 
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HCC receiving trans-arterial radioembolization (TARE) as elective treatment 
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FIGURES LEGEND 
 
Figure 1. Overall survival (panel A) and progression-free survival (panel B) of 120 patients with 
PVTT treated with TARE 
Figure 2.  Proposed point system according to β regression coefficients of the final Cox model built 
on the three variables independently related to post-TARE patients’ survival. Overall survival 
according to prognostic stratification.  
0 points, favourable prognosis: continuous line; 2-3 points, intermediate prognosis: interrupted line; 
>3 points, dismal prognosis: dotted line. 
Figure 3. Baseline CT scans (A), planar scintigrams after 99Tc-MAA (B) and CT scans 6 months 
after TARE (C) in patients with HCC and PVTT. Arrows show PVTT before and after treatment. a 
recanalization of the occluded portal branch may be observed, confirming a favourable response to 
the treatment. 
Panel 1: HCC of segment 4 associated with type 1 PVTT (segmental, branch for segment 4). 
Panel 2: HCC of segments 5-8 associated with type 2 PVTT (secondary order branch, anterior 
branch of right portal vein). 
Panel 3: Bulky HCC of the right lobe of the liver associated with type 3 PVTT (first order branch, 
right portal vein). 
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HIGHLIGHTS 
• A prognostic score for post-TARE survival in patients with HCC and PVTT is proposed 
• Bilirubin, PVTT extension and tumor burden were independently related to survival  
• The combination of these factors allowed identifying three prognostic categories 
• The proposed prognostic categorization may allow better treatment allocation 
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Table 1. Baseline characteristics of the study population 
 
Variable N (%) or Median (IQR) 
Age 64 (56-72) 
Sex (Male) 102 (85.0%) 
Etiology of cirrhosis 
- HCV 
- HBV 
- HBV+HCV 
- Alcohol 
- Other 
 
55 (45.8%) 
28 (23.3%) 
6 (5.0%) 
18 (15.0%) 
13 (10.8%) 
ECOG Performance Status 
- 0 
- 1 
 
115 (95.8%) 
5 (4.2%) 
Bilirubin (mg/dL) 0,82 (0.57-1.31) 
Presence of detectable ascites (yes) 9 (7.5%) 
Child-Pugh score 
- A 
- B7 
 
112 (93.3%) 
8 (6.7%) 
MELD score 8 (7-10) 
ALBI grade 
- grade 1 
- grade 2 
- grade 3 
 
62 (51.7%) 
57 (47.5%) 
1 (0.8%) 
AFP (ng/mL) 85,3 (9,2-1183,3) 
Previous TACE (yes) 37 (30.8%) 
PVT grade
21
 
-PV1 
-PV2 
-PV3 
 
53 (44.2%) 
37 (30.8%) 
30 (25.0%) 
Invasion of hepatic veins 
- Absent 
- Present 
 
110 (91.7%) 
10 (8.3%) 
Maximum diameter (mm) 73.5 (58.3-109.8) 
Multifocal (yes) 99 (82.5%) 
Tumor burden (>50%) 24 (20.0%) 
Pattern 
-Nodular 
-Infiltrative 
 
36 (30.0%) 
84 (70.0%) 
Tumor distribution 
- Unilobar 
- Bilobar 
 
68 (56.7%) 
52 (43.4%) 
Administered activity (GBq) 
Administered spheres (*10
6
/GBq) 
2.6 (1.9-3.7) 
1 (1-1) 
Planning method for dosimetry§ 
- Method 1 
- Method 2 
- Method 3 
 
18 (15%) 
77 (64.2%) 
25 (20.8%) 
Abbreviations: IQR, Interquartile Range; HCV, Hepatitis C Virus; HBV, Hepatitis 
B Virus; ECOG, Eastern Cooperative Oncology Group; MELD, Model for End 
stage Liver Disease; AFP, Alfa-Fetoprotein; TACE, Trans-Arterial 
Chemoembolization; PVT, tumoral Portal Vein Thrombosis. 
§ See text (methods section) for the description of the three different planning 
methods. 
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Table 2. Uni- and multivariable analysis on overall survival on 120 patients with PVTT-associated 
HCC receiving trans-arterial radioembolization (TARE) as elective treatment 
 
Variable 
Univariable analysis Multivariable analysis 
Median OS, months (95% CI) p HR (95%CI) p 
Age 
-≤65 
->65 
 
9.7 (7.1-12.3) 
21.1 (12.0-30.2) 
.010  
Ref 
.868 (.554-1.361) 
.537 
Sex 
- Male 
- Female 
 
13.0 (10.0-16.0) 
23.0 (6.2-39.8) 
.258   
Etiology of cirrhosis 
- HCV 
- HBV 
- HBV+HCV 
- Alcohol 
- Other 
 
14.1 (10.5-17.7) 
12.8 (8.1-17.5) 
9.5 (1.4-17.6) 
30.8 (19.9-47.7) 
9.3 (7.3-11.3) 
.617   
ECOG PS 
- 0 
- 1 
 
13.7 (10.5-16.9) 
40.5 (n.e.-n.e.) 
.207   
Bilirubin  
- ≤ 1.2 mg/dL 
- > 1.2 mg/dL 
 
16.0 (13.5-18.5) 
9.5 (8.8-10.2) 
.019  
Ref 
1,636 (1,030-2,597) 
.037 
Presence of ascites 
- no 
- yes 
 
14.1 (10.6-17.6) 
12.0 (5.2-18.8) 
.617   
Child-Pugh 
- A 
- B7 
 
14.1 (10.9-17.3) 
7.5 (3.8-11.2) 
.864   
MELD 
- ≤ 9 
- >9 
 
14.3 (10.9-17.7) 
11.4 (5.8-17.0) 
.484   
ALBI 
- grade 1 
- grade 2-3 
 
16.0 (14.1-17.9) 
14.1 (10.7-17.5) 
.350   
AFP 
- ≤ 1000 ng/mL 
- > 1000 ng/mL 
 
16.4 (11.9-21.0) 
9.2 (7.2-11.2) 
.003  
Ref 
1.433 (.877-2.344) 
.151 
Previous TACE 
- no 
- yes 
 
14.3 (10.8-17.8) 
11.5 (7.0-16.0) 
.166   
PVT grade 
-PV1 
-PV2 
-PV3 
 
28.0 (10.7-45.3) 
12.0 (6.1-17.9) 
8.2 (5.7-10.8) 
<.0001  
Ref 
1,900 (1,126-3,205) 
3,017 (1,793-5,074) 
<.0001 
Invasion of hepatic veins 
- Absent 
- Present 
 
13.7 (10.4-16.9) 
15.8 (2.4-29.2) 
.925   
HCC Maximum diameter 
 - ≤ 50 mm 
- > 50 mm 
 
21.7 (12.6-30.8) 
11.6 (7.8-15.4) 
.057   
HCC Number of nodules 
- single 
- multifocal 
 
16.6 (3.9-29.3) 
12.0 (8.8-15.2) 
.350   
Tumor burden  <.0001  <.0001 
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- ≤ 50% liver volume 
- > 50% liver voume 
16.0 (13.7-18.3) 
6.4 (5.2-7.6) 
Ref 
2,642 (1,608-4,342) 
HCC Pattern 
-Nodular 
-Infiltrative 
 
25.2 (5.3-45.1) 
10.1 (6.7-13.4) 
.021  
Ref 
1.379 (.828-2.297) 
.216 
Tumor distribution 
- Unilobar 
- Bilobar 
 
16.1 (9.3-22.9) 
12.0 (8.0-16.0) 
.244   
Planning method for 
dosimetry 
- method 1 
- method 2 
- method 3 
 
 
11.6 (4.3-18.9) 
15.4 (11.5-19.3) 
13.7 (9.6-17.8) 
.664   
Abbreviations: 95% CI, 95% Confidence Interval; HR, Hazard Ratio; HCV, Hepatitis C Virus; HBV, Hepatitis B Virus; 
ECOG, Eastern Cooperative Oncology Group; PS, Performance Status; n.e., not evaluable; MELD, Model for End stage 
Liver Disease; AFP, Alfa-Fetoprotein; TACE, Trans-Arterial Chemoembolization; PVT, tumoral Portal Vein Thrombosis. 
 
 
 
 
Table 4. Comparison of outcomes among different prognostic categories 
Category Median OS, 
months  
(95% IC) 
1-yr 
survival 
3-yrs 
survival 
Median PFS, 
months  
(95% IC) 
HCC 
progression 
within 3 
months 
Liver 
decompensation 
within 3 months 
0 points (31 pts): 
favourable 
prognosis 
32.2 (25.9-38.5) 80.6% 42.1% 14.1 (6.9-21.3) 6.5% 3.2% 
2-3 points (52 pts): 
intermediate 
prognosis 
14.9 (10.6-19.2) 57.6% 18.7% 6.2 (4.2-8.2) 9.6% 9.6% 
> 3 points (37 pts): 
dismal prognosis 
7.8 (5.4-10.2) 24.0% 0% 4.1 (3.0-5.2) 16.9% 21.6% 
 
 
 
 
